tbuckley/cabot-search huggingface dataset:
SAT0213 Determination of bone erosions in patients with arthritis by ultrasonography, mri and conventional radiography
Authors: L Terslev, A Savnik, H Christensen, E Qvistgaard, S Torp-Pedersen, B Danneskiold-Samsoe, H Bliddal
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> Conventional radiography (CR) is the standard of reference for detection and quantification of destruction in arthritis. However several studies<sup>1,2</sup> have shown that Magnetic Resonance Imaging (MRI) may be superior to CR in the detection of bone erosion while the use of ultrasonography (US) has not yet been fully clarified. <h3>Objectives</h3> To compare CR with US and MRI in detecting bone erosions in patients with arthritis. <h3>Methods</h3> 16 patients (9 women and 7 men, median age 50,5 years, range (31–69)) with arthritis were included and examined by CR in 2 planes with Nørgaard views, US with a 15 MHz linear transducer in longitudinal scans consecutively covering the whole joint and by 1,5 T MRI with T1-weighted images. Only wrist, 2nd and 3rd MCP joints were evaluated. A total of 106 bone surfaces in the hands were examined by US (45 joints) and 112 bone surfaces by MRI and CR (48 joints). Each imaging modality was evaluated independently. Erosions in CR were evaluated on a standardised sheath. An US erosion were defined as a defect in the bone cortex visualised in the longitudinal scan and different from known US bone irregularities due to tendon tracks etc. A MRI erosion was defined as a focal loss of signal intensity within the bone. For all imaging modalities the erosions were marked ± erosion in the bone surface examined. <h3>Results</h3> US detected a total of 36 bone surfaces with erosions, MRI 29 and CR 7. US and MRI agreed on 76 of 106 surfaces (72%), Kappa = 0,33; US and CR agreed on 74 of 106 surfaces (70%), Kappa 0,14 and MRI and CR agreed on 86 of 112 surfaces (77%), Kappa 0,24. <h3>Conclusion</h3> Of the three imaging modalities US and MRI were in closest agreement and both more sensitive than CR. Differences in the US and MRI interpretations of erosions remain to be clarified. <h3>References</h3> Klarlund M, <i>et al</i>. Magnetic resonance imaging, radiography and scintigraphy of the finger joints: one year follow up of patients with early arthritis. Ann Rheum Dis 2000;59:521–8 Backhaus M, <i>et al</i>. Arthritis of the finger joints. Arthritis Rheum. 1999;42:1232–45
Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma
Authors: Davendra P. S. Sohal, Mai Duong, Syed A. Ahmad, Namita S. Gandhi, M. Shaalan Beg, Andrea Wang-Gillam, James L. Wade, E. Gabriela Chiorean, Katherine A. Guthrie, Andrew M. Lowy, Philip A. Philip, Howard S. Hochster
Journal: JAMA Oncology (2021)

Clinical outcomes after curative treatment of resectable pancreatic ductal adenocarcinoma (PDA) remain suboptimal. To assess the potential of early control of systemic disease with multiagent perioperative chemotherapy, we conducted a prospective trial.
Generalized Asymptomatic Skin Nodules in a Young Man
Authors: Yuchieh Lin, Xixue Chen, Yang Wang
Journal: JAMA Oncology (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Transcolonic endoscopic appendectomy: a novel natural orifice transluminal endoscopic surgery (NOTES) technique for the sessile serrated lesions involving the appendiceal orifice
Authors: Tao Chen, Aiping Xu, Jingjing Lian, Yuan Chu, Haibin Zhang, Meidong Xu
Journal: Gut (2021)

With the advancement in endoscopic technology, the discovery of novel endoscopic techniques such as endoscopic full-thickness resection (EFTR) provides new contents for natural orifice transluminal endoscopic surgery (NOTES) and endoscopic therapeutic options for patients with gastrointestinal lesions. Here, we present transcolonic endoscopic appendectomy as an expansion of full thickness resection with extraluminal dissection of the appendix for minimally invasive treatment of the sessile serrated lesions (SSLs) deeply involving the appendiceal orifice; final closure is done by endoloop and clip placement. The procedure was successful in four patients with good follow-up results at the 3 months colonoscopic control. Generally, transcolonic endoscopic appendectomy extends endoscopic resection technique and will promisingly replace combined endoscopic and laparoscopic surgery technique. This technique should be studied further.

SSLs are colorectal lesions with malignant potential1 and should be removed as accurately as possible.2 In dilemma, more than half of the appendiceal adenomas are SSLs3 4 and therapeutic methods are controversial: endoscopic resection, extended laparoscopic appendectomy or combined laparoscopic appendectomy is traditionally optional.1 Surgical resection remains the standard and endoscopic resection is sometimes performed as an alternative to surgical intervention. However, conventional endoscopic resection of SSLs involving the appendiceal orifice has very critical limitations: endoscopic resection into the appendiceal orifice deeply itself carries a risk of appendicitis and it cannot guarantee a negative deep margin for lesions growing into the lumen of the appendix.2 To overcome these disadvantages, we present a novel NOTES technique, transcolonic endoscopic appendectomy, for the SSL involving the appendiceal orifice. This technique takes advantage of EFTR technique, which includes the endoscopic full-thickness incision and defect closure techniques. Here, we report a series of patients with the SSLs deeply involving the appendiceal orifice removed by transcolonic endoscopic appendectomy technique (figure 1). Patient demographics, procedure details, outcomes, histology and follow-up after …
THU0194 Digital vasculitis in a patient with rheumatoid arthrits: good response on anti-tnf blockade
Authors: FH Van den Hoogen, MM Zandbelt, A Den Broeder, LB Van de Putte
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> Rheumatoid arthritis (RA) may be complicated by vasculitis. Vasculitis usually affects small vessels of the skin causing nailfold infarcts, but may also affect larger vessels and cause severe damage to internal organs. In such cases, treatment with high doses of corticosteroids or other immunosuppressive drugs may be necessary. TNF-alpha blockade has been shown to be an effective and safe treatment for RA, but thus far no reports have addressed the effect of TNF-alpha blockade on extra-articular manifestations of RA, such as vasculitis. <h3>Objectives</h3> We report a patient with RA and nailfold infarcts which repeatedly disappeared for several weeks following monthly i.v. injections with an anti-TNF alpha receptor fusion protein. <h3>Methods</h3> A 46 year old woman was diagnosed as having rheumatoid factor positive, erosive RA in 1982. Due to the uncontrollable disease she was included in 1994 in a study with Ro 45‑2081, a fusion protein combining two p55 TNF receptors with the Fc component of an IgG human antibody (Roche, Basel, Switzerland, sTNFR:Fc). After a three months placebo controlled phase she was treated with 50 mg sTNFR:Fc every four weeks. <h3>Results</h3> Clinical response was impressive with swollen joint counts decreasing from 32 to 5 and C-reactive protein CRP levels declining from 95 at baseline to 20 after the first injection. Low disease activity was sustained for the following years. Besides sTNFR:Fc her medication consisted of oral prednisone 5 mg a day and occasionally paracetamol 500 mg. In the spring of 1999 she first noticed nailfold infarcts on the fingers of both hands. These lesions disappeared after every injection of sTNFR:Fc and reappeared three weeks thereafter when the clinical effects of sTNFR:Fc were decreasing. This effect on the digital vasculitis has been well documented during several cycles of sTNFR:Fc administration. <h3>Conclusion</h3> The prompt disappearance of nailfold infarcts after sTNFR:Fc administration observed in our patient strongly suggests a therapeutic effect of sTNFR:Fc on active vasculitis. This observation raises the question whether blocking of TNF-alpha might also be effective in more severe forms of vasculitis and possibly other extra-articular manifestations of RA, some of which are life threatening and are currently treated with high doses of corticosteroids and immunosuppressive drugs.
Inactivation of E-cadherin by Trop-2 drives colon cancer metastasis.
Authors: Saverio Alberti, Emanuela Guerra, Donato F. Altomare, Raffaella Depalo, Marco Trerotola
Journal: Journal of Clinical Oncology (2021)

105 Background: Tumor metastasis is the main cause of death of colon cancer patients and the biggest hurdle for cancer cure. We set to identify decisive drivers and of pivotal therapy targets for colon cancer metastasis. Methods: IHC analysis quantified the expression of target molecules in primary tumors and metastases. Cell-cell adhesion capacity was assessed in vitro and in HCT116 colon cancer cell spheroids. Pre-clinical models of orthotopic growth of KM12SM colon cancer cells and metastatic diffusion to the liver were utilized to assess metastatic spreading force of wtTrop-2 and of the constitutively-active, tail-less form of Trop-2 (Δcyto). Xenotransplant and metastasis transcriptomes were analyzed for differential induction of EMT determinants. Kaplan–Meier plots were used to illustrate survival and metastatic relapse in independent case series of colon cancer patients. Results: wtTrop-2 was shown to induce wound-healing. ΔcytoTrop-2 further increased cell migration ability. Both wtTrop-2 and ΔcytoTrop-2 induced resistance to apoptosis in vitro and in vivo. wtTrop-2 strikingly increased the metastatic capacity of KM12SM cells, raising metastasis rates from 45% for control cells to 90% for wtTrop-2 transfectants. The constitutively-active ΔcytoTrop-2 further boosted metastatic spreading, with metastatic livers reaching up to four times their normal size. Cancer metastases revealed high levels of E-cadherin, in the absence of transcriptional down-regulation. EMT transcription factors were largely missing from Trop-2-activated cells. Rather, binding to Trop-2 was shown to cause the release of E-cadherin from the cytoskeleton, loss of cell-cell adhesion and activation of β-catenin. This global, Trop-2/E-cadherin/β-catenin-driven pro-metastatic program was recapitulated in colon cancer patients and was shown to impact on colon cancer metastatic relapse and overall patient survival. Conclusions: We identify Trop-2-driven functional inactivation of E-cadherin as a widespread driver of metastatic diffusion in colon cancer, opening novel avenues for personalized diagnostic procedures and anti-cancer therapies. [Table: see text]
AB0413 INVESTIGATION OF THE ASSOCIATION OF CARDIOVASCULAR EVENTS AND ANTI- SS-A ANTIBODIES AS RISK OF DEVELOPMENT IN PATIENTS WITH LUPUS NEPHRITIS FROM THE LUNA REGISTRY: A CROSS-SECTIONAL STUDY
Authors: T. Igawa, K. Ichinose, M. Okamoto, A. Takatani, N. Yajima, K. E. Sada, R. Yoshimi, Y. Shimojima, S. Ono, H. Kajiyama, S. Sato, M. Fujiwara, A. Kawakami
Journal: Annals of the Rheumatic Diseases (2020)

Background: Cardiovascular disease(CVD) has been identified as a major cause of morbidity and mortality in patients with lupus nephritis(LN) 1) 2) . There is a clear causal relationship between the onset of neonatal lupus (cardiac complications) and SS-A antibodies 3) 4) , but no association has been reported in adults. In recent years, there have been reports from overseas that suggest the association between CVD and anti-SS-A antibody in adult systemic lupus erythematosus (SLE) patients 5) 6) . So far, no studies have not been reported to evaluate the relationship between anti-SS-A antibody and the risk of developing CVD in LN in a large cohort of patients with SLE in Japan. Objectives: The aim of this study was to evaluate the association between anti-SS-A antibody and the risk of developing CVD in LN patients using a multicenter registration study [Lupus registry of nationwide institution (LUNA)] in Japan. Methods: We identified 931 patients diagnosed with SLE in the Lupus registry of nationwide institution (LUNA), and further identified 275 LN patients with known the presence or absence of both development of CVD and presence of anti-SS-A antibody. We defined the exposure factor as anti-SS-A antibody, and the outcome as CVD. SELENA-SLEDAI score (at diagnosis), eGFR &lt;60%, HbA1c, BMI, and steroid pulse treatment history were used as confounding factors and we analyzed using logistic regression analysis. Results: We found 68 patients (24.7%) complicated with CVD, including percarditis (7.3%), cerebrovascular disorder (6.2%), peripheral Arterial Disease (6.2%), Ischemic heart disease (2.9%), venous thromboembolism (2.9%), pulmonary hypertension (1.5%), vulvular heart disease (1.1%), and cardiomyopathy (0.4%). In univariate analysis, there was no significant difference in the occurrence of CVD depending on the presence or absence of anti-SS-A antibody (p = 0.32), and the results of multivariate analysis showed no significant difference in anti-SS-A antibody [p = 0.23, odds: 0.41, 95% confidence interval (0.09-1.89)]. Conclusion: The association between anti-SS-A antibody and the development of CVD in LN patients in Japan has not been identified. References: [1]Lupus. 2000;9(3):166-9 [2]Arthritis Rheum.2019 Mar;71(3):403-410, [3]J Intern Med 265:653-662, 2009 [4]Nat Clin Pract Rheumatol 5:139-148, 2009 [5]Ann Rheum Dis 1990;49:627-629 [6]Chest. 2018 Jan;153(1):143-151. Doi: Disclosure of Interests: None declared
Phase II study of sintilimab combined with FLOT regimen for neoadjuvant treatment of gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Authors: Ning Li, Zhi Li, Qiang Fu, Bin Zhang, Jian Zhang, XiangBin Wan, Chaomin Lu, Jinbang Wang, Wenying Deng, Chen Wei, Yijie Ma, Liangyu Bie, Mengyu Wang, Suxia Luo
Journal: Journal of Clinical Oncology (2021)

216 Background: Perioperative treatments have significantly improved survival in patients with resectable gastric cancer, increasing 5-year overall survival from 23% with surgery alone to 45% with FLOT, Although FLOT has been recognized as the first choice for neoadjuvant chemotherapy in gastric or GEJ adenocarcinoma, its efficacy needs to be improved. Sintilimab, a fully human IgG4 monoclonal antibody that binds to programmed cell death receptor-1 (PD-1), has shown remarkable clinical efficacy in various cancers. We aimed to assess the activity and safety profile of the combination of FLOT and sintilimab for neoadjuvant treatment of gastric or GEJ adenocarcinoma. Methods: In this ongoing, single-arm, phase II study, we recruited patients from Henan Cancer Hospital in China with histopathologically diagnosed resectable gastric or GEJ adenocarcinoma who had clinical T3/N+ or higher stage. Patients were given 4 cycles of FLOT (docetaxel 50 mg/m2, oxaliplatin 80 mg/m2, leucovorin 200 mg/m2, fluorouracil 2600 mg/m2, 24-h infusion on day 1, q2w) in combination with 3 cycles of sintilimab (200mg, iv, d1, q3w), followed by D2 surgery and 4 postoperative cycles of FLOT. The primary endpoint was pathological complete response (pCR). The secondary endpoints included major pathological remission (MPR) and R0 resection rate and adverse events . Results: A total of 20 patients were enrolled in the study between Aug 10 2019 and Sep 15 2020. One patient refused surgery, one person's disease progressed. Two patients have not yet completed neoadjuvant treatment . 16 pts who experienced D2 resection, 10 (62.5%) achieved major pathologic response (MPR), including 3 (18.8%) with a pathologic complete response (pCR) in primary tumor. The R0 resection rate was up to 93.8%, The grade 3 or 4 treatment-related adverse events (TRAE) included lymphopenia(25%), anaemia (20%),fatigue (20%),leucopenia (15%), neutropenia (5%), diarrhea(5%), Alanine aminotransferase increased(5%),There was no surgical delays or unexpected surgical complications related to drug toxicity. Conclusions: Neoadjuvant combination of sintilimab and FOLT is a safe and efficacious treatment option for patients with gastric or GEJ adenocarcinoma, 18.8% pCR rate and 62.5%MPR rate is encouraging. Our clinical study is still enrolling, and the survival effects are under follow up. Clinical trial information: NCT04341857.
FRI0089 Il10G promoter polymorphism of the interleukin 10 (il10) in spanish systemic lupus erythematosus (sle) patients
Authors: S Rosado-Garcia, MJ Citores, T Martin-Donaire, I Rua-Figueroa, I Garcia-Laorden, C Rodriguez-Lozano, P Perez-Aciego, C Rodriguez-Gallego, A Durantez
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> IL10 is a pleiotrophic cytokine that inhibits the antigen specific activation of Th1 clones by reducing both the antigen presenting capacity and the production of pro-inflammatory cytokines by monocytes. It is also a potent activation and differentiation factor for B lymphocytes. SLE patients show increased IL10 serum levels associated with the pathogenesis of the disease. Peripheral blood mononuclear cells from SLE patients, and their relatives, constitutively produce high levels of the cytokine, suggesting an hereditary component in IL10 production. Anti-IL10 antibodies administration to SLE patients may be beneficial in the management of refractory cases. The IL10 gene promoter contains two dinucleotide repeats (microsatellites): IL10G and IL10R, close to transcription factor binding sites, probably playing an important role in the transcription regulation. <h3>Objectives</h3> To evaluate the association of the IL10G microsatellite with SLE in Spanish patients. <h3>Methods</h3> 80 unrelated SLE patients from Canary Islands (Spain) fulfilling at least four of the ACR criteria and 79 sex-matched healthy donors were included. A segment of the IL10 gene containing the microsatellite was amplified by PCR and the resulting products were electrophoresed in denaturing polyacrilamide gels. Chi-square test was used for statistical analysis. <h3>Results</h3> No particular IL10G allele was found to be significantly associated with SLE. Neverthaless, we found an elevated risk of serositis in carriers of the allele 19 (p = 0.007), a significant association of the 19/23 genotype with seizures (p = 0.018), and a reduced risk of renal disorder (p = 0.047) and thrombocytopenia (p = 0.049) in carriers of the allele 23. <h3>Conclusion</h3> Although IL10G alleles seem not to influence susceptibility to SLE in Spaniards, some of them may be related to the presence of several clinical manifestations of the disease.
THU0602 EXTENDED BONE HYDATIDOSIS IN THE HIP AND FEMUR WITH EXTENSION TO THE SOFT PARTS: A CASE REPORT
Authors: M. Hassayoun, S. Boussaid, E. Hannech, S. Jemmali, S. Rekik, E. Cheour, H. Sahli, M. Elleuch
Journal: Annals of the Rheumatic Diseases (2020)

Background: Osseous hydatid cyst is an uncommon disease with weak response to treatment.hydatid disease should be included in the differential diagnosis of cystic lesions of bone in endemic regions. Bone cysts account for only 0.5 to 2.5% of all hydatid cysts in humans. Objectives: To report a case of osseous hydatid disease extended on hip and femur Methods: We report a case of osseous hydatid disease Results: A 49 YEAR OLD BRICKLAYER, with no past-medical history and no animal contact, was admitted to our department for a left hip pain. the patient was apyretic and in a good general health condition. He had a very painful walk. the mobilility of the left hip joint was very painful and restricted. The pelvis X-rays showed osteolytic lesions in the ischiopubic branch and in the left femur and proximal extremity of the tibia. The C-Reactive protein value, the protein electrophoresis were normal. tumor markers test was negative. An ultrasound of the hip showed a low abondance intra-articular effusion. The Pelvic MRI showed multilocular appearance extending over the bone and muscle with breach of the bone cortex of the femur very suggesting of the diagnosis of a bony and muscular echinococcosis. NO other localization of hydatidosis were detected, body ct scan was normal Conclusion: Hydatid disease occurs worldwide and mainly associated with sheep farming. The liver and lungs are the most common locations. Bone cysts are uncommon but severe. Although immunofluorescent assays are useful, the final diagnosis depends on histology. The treatment is almost surgery. Recurrence is common Disclosure of Interests: None declared
Vaccines against hepatitis C: a travel into neutralisation space
Authors: Jens Bukh
Journal: Gut (2021)

Since studies performed nearly 50 years ago on patients with post-transfusion hepatitis indicated the existence of HCV as the cause of chronic liver disease, in discoveries recently recognised by the Nobel Prize, at least 25 million people have died from chronic sequelae of this insidious infection, including liver cirrhosis and hepatocellular carcinoma.1 Currently, at least 400 000 people die due to hepatitis C-related diseases, annually, despite the availability of curative direct-acting antivirals.2 Further, there is no prophylactic vaccine against this virus to prevent the nearly 2 million new cases annually, of which 75% result in persistent lifelong infections that for most remain undiagnosed.2 In fact, only very few vaccine candidates have advanced to clinical trials; most recently a T cell based vaccine, despite induction of robust immune responses, failed to lower the chronicity rate following HCV exposure.3 This stands in contrast to the development of effective antibody-based vaccines against SARS-CoV-2, less than 1 year after the first description of its associated disease COVID-19.4 Thus, it would be important to consider which molecular features unique to HCV virus neutralisation challenges vaccine efforts, and to seek solutions by the lessons learnt from COVID-19 to finally change the trajectory towards universal vaccination against HCV. In this issue of Gut , Bankwitz et al 5 explored infectious cell culture systems to advance testing for broadly reactive neutralising antibodies (NtAb) against HCV in patients and in …